The number and activity of Tregs in lung cancer are associated with poor clinical outcomes, and an increase in PD1+ Tregs populations could be observed in patients with NSCLCs resistant to PD-1/PDL-1 therapy. This evidence concerns the gene CD274 and lung carcinoma.